Insulin kinetics during HyperInsulinemia Euglycemia Therapy (HIET)



Similar documents
A Type 1 Diabetic Model. A Thesis. Submitted to the Faculty. Drexel University. Brian Ray Hipszer. in partial fulfillment of the

Abdulaziz Al-Subaie. Anfal Al-Shalwi

Glucose-Insulin System based on Minimal Model: a Realistic Approach

Introduction to Animal Systems

CLOSED LOOP MODEL FOR GLUCOSE INSULIN REGULATION SYSTEM USING LABVIEW

Basal Insulin Analogues Where are We Now?

EFFIMET 1000 XR Metformin Hydrochloride extended release tablet

Milwaukee School of Engineering Case Study: Factors that Affect Blood Pressure Instructor Version

A Fuzzy Controller for Blood Glucose-Insulin System

Pharmaceutical Management of Diabetes Mellitus

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure

April 18, 2008 Dr. Alan H. Stephenson Pharmacological and Physiological Science

Supplementary appendix

Automatic Blood Glucose Control in Diabetes

B. Braun Space GlucoseControl (SGC)

Nursing 113. Pharmacology Principles

Adrenergic agonists:-

Insulin therapy and exercise

A Virtual Type 1 Diabetes Patient

Updates in Insulin Injection Technique: Data and Recommendations

Algorithms for Glycemic Management of Type 2 Diabetes

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

LESSON TWO: COMPARE AND CONTRAST TYPE 1 AND TYPE 2 DIABETES

Insulin dosage based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

Self-tuning Insulin Adjustment Algorithm for Type I Diabetic Patients Based on Multi-Doses Regime.

ACID- BASE and ELECTROLYTE BALANCE. MGHS School of EMT-Paramedic Program 2011

CENTER FOR DRUG EVALUATION AND RESEARCH

INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco

AN INTELLIGENT SUPPORT SYSTEM FOR DIABETIC PATIENTS

Practical Applications of Insulin Pump Therapy in Type 2 Diabetes

STAGES OF SHOCK. IRREVERSIBLE SHOCK Heart deteriorates until it can no longer pump and death occurs.

Adrenergic receptors lec 9, part 2. 16/10/2014 Dr. Laila M. Matalqah Rama Kamal Ali Treany

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

SLIDING SCALE INSULIN ASPART PROTOCOL PLAN

Impact of metoprolol on insulin sensitivity in the ICU

Absorption of Drugs. Transport of a drug from the GI tract

Physiology and Pharmacology

Advanced Practice Provider Academy

Mind the Gap: Navigating the Underground World of DKA. Objectives. Back That Train Up! 9/26/2014

Diabetes Expert Witness on: Diabetic Hypoglycemia in Nursing Homes

Biology 224 Human Anatomy and Physiology II Week 8; Lecture 1; Monday Dr. Stuart S. Sumida. Excretory Physiology

Alternative method for delivering insulin using continuous subcutaneous insulin infusion (CSII) open loop system

[ ] POCT glucose Routine, As needed, If long acting insulin is given and patient NPO, do POCT glucose every 2 hours until patient eats.

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A

Managing the Hospitalized Patient on Insulin: Care Transition. Catie Prinzing MSN, APRN, CNS

THE availability of a simulation model of the glucose-insulin

External Insulin Pumps Corporate Medical Policy

The Background for the Diabetes Detection Model

University College Hospital. Sick day rules insulin pump therapy

Regulation of Metabolism. By Dr. Carmen Rexach Physiology Mt San Antonio College

Lothian Diabetes Handbook MANAGEMENT OF DIABETIC KETOACIDOSIS

Chapter 2 Vasopressors and Inotropes

Sweet-taste receptors, glucose absorption and insulin release: Are LCS nutritionally active?

Updates for your practice March, Vol 2, Issue 14 TLALELETSO. Managing Complicated Diabetes

DIABETIC EDUCATION MODULE ONE GENERAL OVERVIEW OF TREATMENT AND SAFETY

CYCLING AND DIABETES Conrad Earnest, PhD, FACSM

A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or

X-Plain Diabetes - Introduction Reference Summary

ADRENERGIC AND ANTI-ADRENERGIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

Homeostatic Model Assessment (HOMA)

Inotropes/Vasoactive Agents Hina N. Patel, Pharm.D., BCPS Cathy Lawson, Pharm.D., BCPS

Diabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C

Chapter 23. Composition and Properties of Urine

Emergency Fluid Therapy in Companion Animals

Onset Peak Duration Comments

Basal Rate Testing Blood sugar is affected at any time by 1) basal insulin 2) food (carbohydrate) intake 3) bolus insulin (meal time and correction)

Actions of Hormones on Target Cells Page 1. Actions of Hormones on Target Cells Page 2. Goals/ What You Need to Know Goals What You Need to Know

A list of all medications you are taking also include any vitamins, supplements, over-the-counter medicines, or herbal products

There seem to be inconsistencies regarding diabetic management in

Student pharmacists level of confidence in providing DSME prior to entering P4 rotations

Endocrine Responses to Resistance Exercise

Medication Utilization. Understanding Potential Medication Problems of the Elderly

Class time required: Two 40-minute class periods + homework. Part 1 may be done as pre-lab homework

My Doctor Says I Need to Take Diabetes Pills and Insulin... What Do I Do Now? BD Getting Started. Combination Therapy

Management of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)

Chapter 25: Metabolism and Nutrition

Diabetes mellitus 1 عبد هللا الزعبي. pharmacology. Shatha Khalil Shahwan. 1 P a g e

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.

Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008

Linda Young, RN, MS, FRE, BC Nursing Program Specialist South Dakota Board of Nursing

VASOPRESSOR AGENTS IN SEPTIC SHOCK

MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY:

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

A Real-Time Insulin Injection System

Introduction. Pathogenesis of type 2 diabetes

EXPLORING THE INTERACTION BETWEEN EXERCISE AND MEDICATION FOR CHRONIC DISEASE: CONSIDERATIONS FOR FITNESS PROFESSIONALS

HUMAN ANATOMY & PHYSIOLOGY MAINTENANCE 30

Model Predictive Control Algorithms for Pen and Pump Insulin Administration

Fundamentals of Anatomy & Physiology Course Outline, Objectives and Accreditation Information

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr

Transcription:

Insulin kinetics during HyperInsulinemia Euglycemia Therapy (HIET) S. Penning 1, P. Massion 2, A.J. Le Compte 3, T. Desaive 1 and J.G. Chase 3 1 Cardiovascular Research Centre, University of Liege, Liege, Belgium 2 Department of Intensive Care, Liege University Hospital, Liege, Belgium 3 Department of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, Christchurch, New Zealand 8th IFAC of Symposium on Biological and Medical Systems 2012

2 Introduction Cardiogenic shock Insulin action HIET Research purpose

Introduction HIET 5 Cardiogenic shock Cardiac pump failure Insufficient tissue perfusion Anaerobic metabolism Cardiac ATP from glucose Glucose supply Glucose ATP Calcium metabolism Vasodilator effects Anti-apoptosis Insulin Energy metabolism Anti-oxidative effects Anti-inflammatory effects Hyper-Insulinemia Euglycemia Therapy (HIET)

Introduction HIET 6 Insulin 1 U/kg/h Dextrose 400 g/day Patient with low insulin sensitivity Hypoglycemic risk Low insulin action Limited glycemia reduction Low exogenous glucose input Increased insulin sensitivity Important insulin action

Introduction Research purpose 7 HIET nowadays Empirical therapy Difficult dosing High risk (hypoglycemia) «Last chance» therapy HIET in the future Model-based protocol Optimal interventions Tightly controlled glycemia Safe and effective therapy 1) Should the insulin-glucose system model be adapted? 2) Should the insulin kinetics be modified at high insulin doses? 3) Is insulin sensitivity decisive for HIET optimisation?

8 Methods Model of the glucose-insulin system

Methods Model 9 Glucose absorption through stomach and gut Insulin injections Central Nervous Endogenous System Uptake glucose production EGP CNS Other insulin-independent glucose uptake p G G d 1 d 2 u ex (1-x L )u en u en =f(e -I(t) ) Endogenous insulin after 1 st pass hepatic filtration PN Plasma Insulin I(t) Blood Glucose G(t) Hepatic clearance n L I 1+α I I n I Kidney clearance n K I receptor binding Interstitial Insulin Q(t) Insulin-dependent glucose removal through receptor-bound insulin SI(t) G Q 1+α G Q Q n C 1+α G Q Interstitial insulin degradation through receptor binding

10 Results and Discussion Comparison between measured and simulated I Model adaptation

I (mu/l) Results 11 Comparison between measured and simulated I Patient 1 5000 4500 4000 3500 3000 Measured I 2500 2000 1500 1000 500 0 0 5 10 15 20 25 30 35 40 45 Time (hours) Measured > Simulated Lower clearance in the model

I (mu/l) Results 13 Comparison between measured and simulated I Patient 2 5000 4500 4000 3500 3000 Measured I 2500 2000 1500 1000 500 0 0 5 10 15 20 25 30 35 40 45 Time (hours) Saturation at high insulin levels Higher clearance in the model Hypothesis: erroneous measurements

I (mu/l) Results 14 Comparison between measured and simulated I Patient 3 9000 8000 7000 Measured I 6000 5000 4000 3000 2000 1000 0 5 10 15 20 25 30 35 40 45 50 Time (hours) Measured > Simulated Lower clearance in the model

I (mu/l) Results 15 Comparison between measured and simulated I Patient 4 10000 9000 8000 7000 6000 Measured I 5000 4000 3000 2000 1000 Measured > Simulated 0 0 5 10 15 20 25 30 35 40 45 50 Time (hours) Lower clearance in the model Saturation at high insulin levels Higher clearance in the model

Results 16 Reduced clearance (0h-10h) Saturated renal clearance Renal tubule receptors Increased clearance (20 > t >10h) Unsaturated renal clearance Alternative insulin receptors? Additional clearance process Elimination via urine? Interstitial space storage? Mechanisms: Time-dependent? Insulin plasma concentration dependent? Insulin exposure dependent? Patient-specific?

I (mu/l) Results 17 Adapted model Patient 3 9000 8000 7000 6000 Measured I 5000 4000 3000 2000 1000 0 0 5 10 15 20 25 30 35 40 45 50 Time (hours)

I (mu/l) Results 18 Adapted model Patient 3 9000 8000 7000 Measured I 6000 5000 4000 3000 2000 1000 0 5 10 15 20 25 30 35 40 45 50 Time (hours)

I (mu/l) Results 19 Adapted model Patient 4 10000 9000 8000 7000 6000 Measured I 5000 4000 3000 2000 1000 0 0 5 10 15 20 25 30 35 40 45 50 Time (hours)

I (mu/l) Results 20 Adapted model Patient 4 10000 9000 8000 7000 6000 Measured I 5000 4000 3000 2000 1000 0 0 5 10 15 20 25 30 35 40 45 50 Time (hours) Additional renal process after 15 hours: 0.7 I

Conclusion 21

Conclusion 22 1) Should the insulin-glucose system model be adapted? YES 2) Should the insulin kinetics be modified at high insulin doses? YES Reduced clearance (0h-10h) Saturated renal clearance Increased clearance (t >10h) Unsaturated renal clearance Additional clearance process Initial saturation Inotropic insulin action Effective HIET Body adaptation (t >10h) Large insulin elimination Uneffective therapy

Thank you for your attention Questions?